Difference between revisions of "NET of unknown primary"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/") |
m |
||
Line 13: | Line 13: | ||
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | '''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.''' | ||
==[https://www.esmo.org/ ESMO]== | ==[https://www.esmo.org/ ESMO]== | ||
− | *'''2015:''' [ | + | *'''2015:''' [https://doi.org/10.1093/annonc/mdv305 Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/26314775/ PubMed] |
==NCCN== | ==NCCN== |
Latest revision as of 23:50, 30 June 2024
0 regimens on this page
0 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- 2015: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PubMed
NCCN
All lines of therapy
- Poorly differentiated or small cell tumors can be treated with small cell lung cancer regimens.
- Moderate to well-differentiated neuroendocrine tumors can be treated with regimens for neuroendocrine tumors.